TypeName: Business Offer
Country: United States
Summary: NLG919 is an orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs).
https://www.bocsci.com/nlg-919-cas-1402836-58-1-item-462741.html
Description: We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.
OfferId: 2229
Name:Alex Brown
Telphone: